Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.
Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has commercialized the product outside of the U.S. for ~15 years.
Within the U.S., Bioventus markets 3-injection HA GELSYN-3 and 5-injection HA SUPARTZ FX. DUROLANE offers a single-injection dosing regimen.
Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.
Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has...
Bioventus entered into an agreement with Galderma to bring DUROLANE knee osteoarthritis treatment to the U.S., and plans to file a Premarket Approval Application with FDA in early 2017.
Galderma manufactures DUROLANE and other hyaluronic acid products. Bioventus purchased the ex-U.S. assets of DUROLANE in 2014, and has commercialized the product outside of the U.S. for ~15 years.
Within the U.S., Bioventus markets 3-injection HA GELSYN-3 and 5-injection HA SUPARTZ FX. DUROLANE offers a single-injection dosing regimen.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
